表紙
市場調査レポート

陰部ヘルペス : パイプライン分析

Genital Herpes - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 232819
出版日 ページ情報 英文 101 Pages
即納可能
価格
本日の銀行送金レート: 1USD=104.18円で換算しております。
Back to Top
陰部ヘルペス : パイプライン分析 Genital Herpes - Pipeline Review, H1 2016
出版日: 2016年02月29日 ページ情報: 英文 101 Pages
概要

陰部ヘルペスは、代表的な性感染症のひとつで、性別に関係なく発症します。この疾患は、単純ヘルペスウイルス(HSV)によって引き起こされ、食欲の減退、発熱、倦怠感、腰部・臀部・大腿部・膝の筋肉の痛み、足の付け根のむくみやリンパ節の痛みが症状として現れます。

当レポートでは、陰部ヘルペス治療薬の開発状況について調査しており、パイプライン製品の概要、治験の段階別の製品概要、主要企業のプロファイル、薬剤のプロファイル、パイプライン製品の最新動向などを提供しています。

イントロダクション

  • 調査範囲

陰部ヘルペスの概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

陰部ヘルペス:企業で開発中の治療薬

陰部ヘルペス:大学/機関で研究中の治療薬

陰部ヘルペス:パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品

陰部ヘルペス:企業で開発中の製品

陰部ヘルペス:大学/機関で研究中の製品

陰部ヘルペスの治療薬開発に従事している企業

  • Admedus Ltd
  • AiCuris GmbH & Co. KG
  • AlphaVax, Inc.
  • Foamix Pharmaceuticals Ltd.
  • Genocea Biosciences, Inc.
  • GenVec, Inc.
  • Immune Design Corp.
  • Immunovaccine, Inc.
  • Mymetics Corporation
  • NanoBio Corporation
  • NanoViricides, Inc.
  • PaxVax
  • Profectus BioSciences, Inc.
  • Sanofi Pasteur SA
  • Spider Biotech
  • Starpharma Holdings Limited
  • Vaccibody AS
  • Vaxart, Inc.
  • Vical Incorporated

陰部ヘルペス:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • acyclovir
  • Aspidasept
  • astodrimer
  • G-103
  • GEN-002
  • GEN-003
  • genital herpes vaccine HSV-2
  • GV-2207
  • HerpeCide-I
  • herpes simplex virus serotype 2 vaccine
  • herpes simplex virus type 1, 2 vaccine
  • herpes simplex virus type 2 vaccine
  • HSV-529
  • pritelivir
  • SB-105A10
  • VCLHB-01
  • VCLHM-01

陰部ヘルペス:最近のパイプライン動向

陰部ヘルペス:休止中のプロジェクト

陰部ヘルペス:開発が中止された製品

陰部ヘルペス:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7639IDB

Summary

Global Markets Direct's, 'Genital Herpes - Pipeline Review, H1 2016', provides an overview of the Genital Herpes pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Genital Herpes, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Genital Herpes and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Genital Herpes
  • The report reviews pipeline therapeutics for Genital Herpes by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Genital Herpes therapeutics and enlists all their major and minor projects
  • The report assesses Genital Herpes therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Genital Herpes

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Genital Herpes
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Genital Herpes pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Genital Herpes Overview
  • Therapeutics Development
    • Pipeline Products for Genital Herpes - Overview
    • Pipeline Products for Genital Herpes - Comparative Analysis
  • Genital Herpes - Therapeutics under Development by Companies
  • Genital Herpes - Therapeutics under Investigation by Universities/Institutes
  • Genital Herpes - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Genital Herpes - Products under Development by Companies
  • Genital Herpes - Products under Investigation by Universities/Institutes
  • Genital Herpes - Companies Involved in Therapeutics Development
    • Admedus Ltd
    • AiCuris GmbH & Co. KG
    • Foamix Pharmaceuticals Ltd.
    • Genocea Biosciences, Inc.
    • GenVec, Inc.
    • Immune Design Corp.
    • Immunovaccine, Inc.
    • Mymetics Corporation
    • NanoBio Corporation
    • NanoViricides, Inc.
    • PaxVax, Inc.
    • Profectus BioSciences, Inc.
    • Sanofi Pasteur SA
    • Shulov Innovative Science Ltd.
    • Starpharma Holdings Limited
    • Vaccibody AS
    • Vaxart, Inc.
    • Vical Incorporated
  • Genital Herpes - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • acyclovir - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Aspidasept - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • astodrimer - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • G-103 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GEN-002 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GEN-003 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • genital herpes vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GV-2207 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Herpecide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • herpes simplex virus [type 1, 2] vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • herpes simplex virus [type 1, 2] vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • herpes simplex virus 2 vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • herpes simplex virus 2 vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • herpes simplex virus 2 vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • herpes simplex virus 2 vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • herpes simplex virus 2 vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • herpes simplex virus 2 vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • herpes simplex virus 2 vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • herpes simplex virus 2 vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • herpes simplex virus 2 vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HSV-529 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pritelivir - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VCLHB-01 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VCLHM-01 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZEP-3 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Genital Herpes - Recent Pipeline Updates
  • Genital Herpes - Dormant Projects
  • Genital Herpes - Discontinued Products
  • Genital Herpes - Product Development Milestones
    • Featured News & Press Releases
      • Feb 03, 2016: Model helps decide drug dose for clinical testing
      • Jan 29, 2016: Genocea Commences Dosing in Phase 2b Study for Genital Herpes Treatment, GEN-003
      • Oct 07, 2015: Genocea Announces Positive Durability Data from 6-Month Analysis of Phase 2 Clinical Trial of Genital Herpes Immunotherapy GEN-003
      • Sep 22, 2015: NanoBio's Genital Herpes Vaccine Demonstrates Efficacy In Guinea Pigs As Both A Prophylactic And A Therapeutic Vaccine
      • Aug 17, 2015: NanoViricides Accelerates its Herpes Drug Development Program
      • Aug 17, 2015: Vaxart to Present at the 6th Euro Global Summit and Expo on Vaccines and Vaccination in Birmingham, UK on August 18, 2015
      • May 20, 2015: Genocea Announces Positive Top-Line Phase 2 Data for Genital Herpes Immunotherapy GEN-003
      • Apr 10, 2015: Admedus has high hopes for Herpes vaccine as dosing commences
      • Jan 07, 2015: Genocea Completes Enrollment Early in Phase 2 Dose Optimization Trial of GEN-003 for Treatment of Genital Herpes
      • Oct 08, 2014: NanoBio To Present Data Demonstrating The Potential For Its Intranasal Vaccine To Protect Against Genital Herpes Infection
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Genital Herpes, H1 2016
  • Number of Products under Development for Genital Herpes - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Genital Herpes - Pipeline by Admedus Ltd, H1 2016
  • Genital Herpes - Pipeline by AiCuris GmbH & Co. KG, H1 2016
  • Genital Herpes - Pipeline by Foamix Pharmaceuticals Ltd., H1 2016
  • Genital Herpes - Pipeline by Genocea Biosciences, Inc., H1 2016
  • Genital Herpes - Pipeline by GenVec, Inc., H1 2016
  • Genital Herpes - Pipeline by Immune Design Corp., H1 2016
  • Genital Herpes - Pipeline by Immunovaccine, Inc., H1 2016
  • Genital Herpes - Pipeline by Mymetics Corporation, H1 2016
  • Genital Herpes - Pipeline by NanoBio Corporation, H1 2016
  • Genital Herpes - Pipeline by NanoViricides, Inc., H1 2016
  • Genital Herpes - Pipeline by PaxVax, Inc., H1 2016
  • Genital Herpes - Pipeline by Profectus BioSciences, Inc., H1 2016
  • Genital Herpes - Pipeline by Sanofi Pasteur SA, H1 2016
  • Genital Herpes - Pipeline by Shulov Innovative Science Ltd., H1 2016
  • Genital Herpes - Pipeline by Starpharma Holdings Limited, H1 2016
  • Genital Herpes - Pipeline by Vaccibody AS, H1 2016
  • Genital Herpes - Pipeline by Vaxart, Inc., H1 2016
  • Genital Herpes - Pipeline by Vical Incorporated, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Genital Herpes Therapeutics - Recent Pipeline Updates, H1 2016
  • Genital Herpes - Dormant Projects, H1 2016
  • Genital Herpes - Dormant Projects (Contd..1), H1 2016
  • Genital Herpes - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Genital Herpes, H1 2016
  • Number of Products under Development for Genital Herpes - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top